TScan Therapeutics, Inc. (TCRX) Tops Q1 EPS by 54c

TScan Therapeutics, Inc. (NASDAQ: TCRX) reported Q1 EPS of $0.26, $0.54 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $2.2 million versus the consensus estimate of $1.2 million.

For earnings history and earnings-related data on TScan Therapeutics, Inc. (TCRX) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Jane Street Took $15 Billion Hit In July Tied To Situational Awareness - Reuters
• Phillips 66, Marathon Merger Talks Collapsed - Semafor